Teva announced the launch of Dutasteride Capsules, the generic version of GlaxoSmithKline’s Avodart.

Avodart is a type I and II 5-alpha reductase inhibitor indicated for benign prostatic hyperplasia, as monotherapy to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery; or in combination with tamsulosin.

Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for testosterone conversion in the skin and liver.

RELATED: Benign Prostatic Hyperplasia Treatments

Dutasteride Capsules are available in a 0.5mg strength in 30- and 90-count bottles.

For more information call (888) 838-2872 or visit